Mitsubishi UFJ Asset Management UK Ltd. Has $1.74 Million Holdings in Illumina, Inc. (NASDAQ:ILMN)

Mitsubishi UFJ Asset Management UK Ltd. lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 116.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,000 shares of the life sciences company’s stock after buying an additional 7,000 shares during the period. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Illumina were worth $1,737,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ILMN. Intech Investment Management LLC acquired a new stake in Illumina during the 2nd quarter valued at $313,000. Pacer Advisors Inc. increased its holdings in Illumina by 71.9% during the 2nd quarter. Pacer Advisors Inc. now owns 31,762 shares of the life sciences company’s stock valued at $3,315,000 after purchasing an additional 13,290 shares in the last quarter. Sei Investments Co. increased its holdings in Illumina by 37.3% during the 2nd quarter. Sei Investments Co. now owns 97,681 shares of the life sciences company’s stock valued at $10,196,000 after purchasing an additional 26,538 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Illumina by 97.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 60,298 shares of the life sciences company’s stock valued at $6,294,000 after purchasing an additional 29,709 shares in the last quarter. Finally, Gabelli Funds LLC increased its holdings in Illumina by 27.6% during the 2nd quarter. Gabelli Funds LLC now owns 6,589 shares of the life sciences company’s stock valued at $688,000 after purchasing an additional 1,425 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

NASDAQ ILMN opened at $141.31 on Wednesday. The business has a 50 day simple moving average of $139.30 and a 200 day simple moving average of $133.99. Illumina, Inc. has a 52-week low of $100.08 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The stock has a market cap of $22.41 billion, a price-to-earnings ratio of -14.19 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same period in the prior year, the business earned $0.33 EPS. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. Analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ILMN shares. UBS Group increased their price objective on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Robert W. Baird lifted their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. JPMorgan Chase & Co. boosted their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. TD Cowen boosted their price objective on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Piper Sandler dropped their price objective on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.63.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.